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Abstract
Bacterial adherence to the acquired dental pellicle, important in dental caries (caries), is mediated
by receptor-adhesins such as salivary agglutinin binding to Streptococcus mutans antigen I/II (I/
II). Ten selected I/II epitopes were chosen to determine their reactivity to human salivary IgA.
Previous studies suggested that a specific HLA biomarker group (HLA-DRB1*04) may have
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differential influence of immune responses to I/II. However, it was not known whether secretory
IgA (SIgA) responses to the selected epitopes from HLA-DRB1*04 positive subjects were
different compared to controls, or across other caries-related factors such as total IgA (TIgA).
Thirty-two total subjects were matched according to HLA type, gender, ethnicity and age. HLA
genotyping, oral bacterial, immunoglobulin and antibody analyses were performed. A large
observed difference emerged with regard to the natural immune reservoir of TIgA in HLA-
DRB1*04 positive subjects, specifically, a 27.6% reduction compared to controls. In contrast to all
other epitopes studied, HLA-DRB1*04 positive subjects also exhibited reduced reactivity to I/II
epitope 834–853. HLA-DRB1*04 positive subjects exhibited lower specific SIgA activity/TIgA to
834–853 and also a lower specific reactivity to 834–853/whole cell S. mutans UA159.
Furthermore, HLA-DRB1*04 positive subjects exhibited lower responses to I/II in its entirety.
The large observed difference in TIgA and the 834–853 reactivity pattern across multiple
measures suggest potentially important connections pertaining to the link between HLA-DRB1*04
and caries.
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1. INTRODUCTION
The natural history of dental caries (caries) and development of the salivary immune
response in humans is multifactorial. Although populated with certain types of oral
streptococci (i.e., Streptococcus salivarius and Streptococcus mitis) as newborns, children
are not infected with Streptococcus mutans permanently until anywhere from 18 to 36
months [1,2]. Permanent infection with mutans streptococci during this period is dominanted
by S. mutans and S. sobrinus—cariogenic agents in caries. Permanent infection with others
of the mutans group does not happen until tooth eruption begins, although we now know this
can happen earlier, but colonizing numbers are lower and harder to detect until primary
molars start erupting. Newborns lack significant levels of secretory IgA (SIgA), but by 12 to
24 months most children have SIgA levels similar to those found in adults.
In 2008, a study was published showing that an Iranian cohort of children with a specific
human leukocyte antigen (HLA) class II allele (HLA-DRB1*04) were 10 times more likely
to have early childhood caries (ECC) [3]. All 79 subjects were between the ages of 12 and
72 months, meaning they would have had time to become permanently infected with mutans
streptococci and to have developed a mature level of SIgA. Their individual host antibody
responses, however, could have only been as good as their “specificity and functional
activity” against the pathogens [4]. The Iranian study did not analyze levels of mutans
streptococci colonization or SIgA. However, it did report that of 35 children who did not
have ECC, 34 of them were HLA-DRB1*04 negative. As is well known, antibodies, such as
SIgA in mucosal immunity, play a major role in immunomodulation and are linked to HLA
genetics because intracellular processes and antigen presentation is modulated by particular
HLA class II (HLA-II) genes. HLA drives T-cell responses, which stimulates B-cell
activation and IgA secretion. Not only have HLA-II alleles been immunopathogenically
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associated with members of the streptococcal family [5, 6], but also other infectious bacteria
[7].
Animal and human studies suggest that HLA-II genes may play a role in the development of
caries. Rat genes corresponding to the HLA region in humans have been found to regulate
immunity against S. mutans [8]. One report indicated that murine genes found in the H-2
region, corresponding to the HLA region in humans, controlled serum IgG response to
particular cariogenic epitopes [9]. The murine H-2 region has a marked effect on clinical
caries susceptibility as well [10].
In Caucasian populations, HLA-DRB1*04 has been suggested as an allele that may increase
caries susceptibility [11,12] whereas, in certain Asian and Brazilian populations, HLA-
DQB1*06 may be a susceptible allele and HLA-DQB1*02 may be a protective allele in the
caries process [13,14]. These agree with other reports that identical diseases may be
associated with different HLA-II alleles in different populations [15,16].
Animal and human studies suggest that HLA immunogentic interactions are important in
modulating a cariogenic infection. Understanding the immunogenetic interactions between
host and microbes, such as S. mutans, is critical in understanding caries, especially when
desiring to improve prevention, diagnosis and detection, as well as therapeutic approaches.
Currently, S. mutans “remains prominent in most molecular genetic profiles of incipient
dental disease, and thus continues to be a reasonable candidate for elimination” [17]. It also
continues to remain the prototypic caries pathogen, and no other species within the oral
microbiome “is yet a serious contender to S. mutans for a role as a worthwhile marker
organism” in the caries process [18]. S. mutans has three surface proteins of major
importance, which aid in attaching to tooth surfaces. These include glucosyltransferases
(GTFs), glucan-binding proteins (GBPs), and antigen I/II (I/II). These proteins have been
vaccine targets for caries. GBPs are surface-associated adhesins that play a substantial role
in architectural development of the biofilm, GTFs are cell-associated and secreted enzymes,
and I/II is a cell-wall anchored adhesin.
Bacterial adherence to the acquired dental pellicle, important in dental caries, can occur even
when other exogenous factors such as sucrose are not present. This is mediated by receptor-
adhesins, such as salivary agglutinin, binding to S. mutans I/II. Antigen I/II is comprised of
several regions (A, V, P and C; Figure 1) that may stimulate salivary IgA reactivity in
infected subjects. As mentioned, previous studies suggested that a specific HLA biomarker
group (HLA-DRB1*04) may have differential influence on immune responses to I/II.
However, it was not known whether secretory IgA (SIgA) responses to the ten selected
epitopes from HLA-DRB1*04 positive subjects were different compared to controls. No
known published study to date has assessed these questions. The goal of this study was to
gain a molecular understanding of S. mutans-induced caries with the objective of future
vaccine design and biomarker identification to predict caries susceptibility.
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2. MATERIALS AND METHODS
2.1. Bacterial Strains
S. mutans UA159 (ATCC 700610), NG8 and PC3370 were used in this study. The UA159
genome can be electronically accessed (access # NC_004350) [19].
2.2. Study Population
Prior to this study, all appropriate IRB approvals were secured. Subjects in this study were
recruited from the TrialNet Natural History Study (TN NHS), which evaluated healthy yet
at-risk for Type I diabetes (T1D) subjects since many of these subjects are HLA-DRB1*04
positive and HLA typing was already done. The study population was divided into two
groups: the control group, an HLA-DRB1*04 negative group (n = 16), and an HLA-
DRB1*04 positive group (n = 16). After completing the informed consent process, subjects
were asked to provide a medical history and prescribed demographic information. Subjects
who were HLA-DRB1*04 positive (as determined from genotyping during Phase 2 or 3
participation of TN NHS, or as determined by genotyping of genomic DNA from saliva
collection as described at the time of the study visit) were invited to participate. Matched
gender, ethnicity and age control subjects testing negative for HLA-DRB1*04 were also
invited to participate.
2.3. Saliva Collection
At the time of the subject’s visit, unstimulated whole saliva was collected and stored at
either −80°C (for bacterial enumeration) or −20°C (for antibody assays) until laboratory
analysis. In some cases, two samples of saliva were collected (the first for antibody and
bacterial analysis and the second for HLA DNA genotyping). For the subjects where DNA
had already been collected and HLA sequenced through the TN NHS, and only one saliva
sample was required, that sample was collected and later divided in the laboratory into two
aliquots, one for bacterial analysis and the other for antibody analysis. Subjects were
instructed to provide at least 5 mL of unstimulated saliva in a 50 mL sterile tube, and were
timed in order to calculate a salivary flow rate. After the samples had been transferred to the
laboratory and vortexed, 0.9 mL was pipetted into another vial and mixed with 0.2 mL of
sterile glycerin, vortexed and stored at −80°C until bacterial analysis. The remainder of the
sample was then divided into 1.5 mL aliquots for antibody analysis and stored at −20°C.
For those subjects requiring HLA genotyping (i.e., TN NHS HLA genotyping data was not
available), a second sample was collected to determine if the participant was HLA-
DRB1*04 positive or negative. For this purpose, 3 mL of stimulated saliva (stimulated for 2
min by chewing on paraffin) was collected with Oragene® DNA sample collection kits
(DNA Genotek, Kanata, Ontario, Canada) and was stored at room temperature.
2.4. HLA Genotyping
Real time-PCR was utilized to determine group-specific HLA-DRB1 alleles on the Roche®
LightCycler® 480 (Roche Diagnostics Corporation, Roche Applied Science, Indianapolis,
IN) in the Hereditary Genomics Laboratory at the University of Kentucky. PCR was carried
out as previously described [20]. Briefly, each PCR reaction (10 ul) contained: 10 ng of
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genomic DNA; 1X of LightCycler480® FastStart DNA Master Hybridization Probes mix
(Roche Diagnostics Corporation); 200 nM HLA-DRB1*04 specific forward primer (5′-GT
TTC TTG GAG CAG GTT AAA C-3′) tailed with M13f-21 (5′-GTA AAA CGA CGG
CCA G-3′); 200 nM DRB-3i reverse primer (5′-C TCG CCI CTG CAC IGT IAA GC-3′
where I = inosin) tailed with the M13 reverse sequence (5′-CAG GAA ACA GCT ATG
AC-3′); 200 nM HLA-DRB-specific fluorogenic probe (5′-FAM-labeled-CGG GCG GTG
ACG GAG CTG GGG C-Black Hole Quencher-3′); and PCR Boost (Biomatrica, Inc., San
Diego, CA). All oligonucleotides were synthesized by Integrated DNA Technologies (IDT;
Coralville, Iowa). The RT-PCR cycling consisted of the following steps: a) initial
denaturation for 10 minutes at 95°C; b) 10 cycles of 95°C for 5 seconds and 65°C for 20
seconds with a single fluorescence reading (465 – 510 nm); c) 25 cycles of 95°C for 5
seconds and 60°C for 20 seconds with a single fluorescence reading; then d) 40°C for 30
seconds cool down. Three cell lines (courtesy of Dr. Janice S. Blum), known to be
homozygous for HLA-DRB1*0401 (Priess human B cell line), heterozygous for HLA-
DRB1*04/HLA-DRB1*01 (Frev B cell line), and negative for HLA-DRB1*04 (Sweig,
Epstein-Barr virus (EBV) immortalized lymphoblastoid (LCL) B cells; homozygous for
HLA-DRB1*1101), were used as controls.
2.5. Bacterial Analyses
Aliquots of whole saliva in glycerin were diluted 1:100 and 1:1000 in sterile saline, double-
plated on Mitis Salivarius agar supplemented with sucrose and bacitracin (MSSB)
(Anaerobe Systems, Morgan Hill, California). The plates were incubated for 48 hours at
37°C and 5% CO2, and subsequently the number of mutans streptococci colonies
enumerated using an automated colony counter (Protocol Synoptic LTD, North Cambridge,
United Kingdom), yielding mutans streptococci colony-forming units/mL (CFU/mL) of
whole saliva.
2.6. Selecting, Synthesizing, and Storing I/II Peptides
Ten antigen I/II peptides that induce immune responses in humans, encompassing several
regions of the intact protein (Figure 1) were selected for analysis based on immunoreactivity
from other studies [21,22]. The following peptides were selected: NAKATYE-
AALKQYEADLAAVKKANAA (361–386), IETGKKPNIWYSLNGKIRAV (803–822),
VPKVTKEKPTPPVKPTAPTK (824–843), PPVKPTAPTKPTYETEKPLK (834–853),
ETEKPLEPAPVEPSYEAEPT (925–944), PTVHFHYFKLAVQPQVNKEI (985–1004),
RNNNDINIDRTLVAKQSVVK (1005–1024), FQLKTADLPAGRDETTSFVL (1025–
1044), TLATFNADLTKSVATIYPTV (1085–1104), and KSVATIYPTVVGGVLNDGAT
(1095–1114). These peptides derived from the A-region (121–447), V-region (448–839), P-
region (840–983), and the C-terminal region (984–1463), respectively. Each peptide was
synthesized (Peptide 2.0, Chantilly, Virginia) and lyophilized at the following purities
(following the same order as above, in percent): 91.1, 92.2, 96.9, 98.0, 95.1, 96.6, 93.6, 80.6,
79.4, and 93.2. Each peptide was dissolved in distilled water to yield a 1 mg/mL stock
solution and stored at −20°C.
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2.7. Enzyme-Linked Immunosorbent Assay (ELISA)
Total IgA, levels of salivary IgA (SIgA) antibodies to I/II epitopes of S. mutans UA159, and
whole cells of S. mutans (UA159, NG8 and I/II-deficient PC3370 on an NG8 background)
were detected using ELISA. Briefly, the total level of IgA (TIgA) in saliva was determined
by a sandwich ELISA, as follows. Goat anti-human IgA (Sigma Chemical Co., St. Louis,
Mo.) was used as the coating antibody and horseradish peroxidase (HRP)-labeled goat anti-
human IgA (Sigma, alpha chain specific) was used as the detecting antibody as previously
described [23]. The plates were read on a SpectraMax 190 microplate spectrophotometer
(Molecular Devices, Sunnyvale, California) at 490 nm. IgA standards were used to calculate
the unkown IgA sample values by linear regression analysis. Calculations were performed
by using the standard curve equation from a log-log function (R2 = 0.991). Total IgA
determinations were accomplished by creating a standard curve from standard
concentrations of human colostral IgA (Sigma: 200 to 0 μg/mL).
A modified ELISA [24] was used to measure human SIgA binding to the ten I/II peptides (1
μg/mL) and 3 formalin-killed strains of S. mutans (UA159, NG8 and an NG8-derived
antigen I/II deficient mutant strain PC3370). For the latter assays, lysed whole S. mutans
cells were used in place of I/II epitopes. Data was also reported as a ratio of each peptide
value divided by the total IgA concentration or reactivity to the three S. mutans whole cell
antigens.
2.8. Data Analysis
All experiments were done in either duplicate or triplicate and are reported as means and
standard errors of the mean. Paired t-tests were used to compare the matched pairs from the
HLA-DRB1*04 positive and control groups. A natural logarithmic transformation of the
variables was used for most analyses due to the non-normal distribution of the data.
3. RESULTS
Figure 1 represents antigen I/II and the varying locations of the 10 epitopes tested. Previous
work has demonstrated that these epitopes are either human salivary IgA targets or elicit
varying degrees of human T- and B-cell responses. HLA drives T-cell responses, which
stimulates B-cell activation and IgA secretion.
HLA-DRB1*04 (hereafter, DRB1*04) positive subjects did not exhibit statistically
significant differences in levels of S. mutans (Figure 2).
Total IgA levels in DRB1*04 positive subjects were lower by 27.6% (Figure 3), and
although not statistically significant, this observed difference has never been reported. This
means that, on average, DRB1*04 positive subjects have 25 μg/mL less TIgA compared to
their negative counterparts. The concentrations of TIgA in all subjects ranged from 15.3 –
420.4 μg/mL, in agreement with a recent report demonstrating TIgA concentrations ranging
from 13.7 – 483.0 μg/mL in 134 healthy individuals [25]. The average control subject
exhibited a TIgA concentration of 89 μg/mL whereas the DRB1*04 positive subject had 64
μg/mL of TIgA.
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DRB1*04 positive subjects also exhibited numerically, but not statistically, higher specific
immunoreactivity to nine out of 10 epitopes compared to controls (Figure 4). However,
DRB1*04 positive subjects exhibited lessened reactivity to epitope 834–853, though not
statistically significant. This epitope’s amino-terminus straddles the carboxy-terminus of the
V region of I/II, and the epitope’s carboxy-terminus encompasses most of the P1 region,
which appears to be a very important interface between all three (A, V, and P) I/II regions.
Though not statistically significant, DRB1*04 positive subjects exhibited lower specific
SIgA activity/TIgA to 834–853, and also a lower reactivity ratio of 834–853/whole cell S.
mutans UA159 (Figure 5). In an indirect measure of immunoreactivity against the entire I/II
antigen (PC3370 background devoid of antigen I/II subtracted from the NG8 wildtype strain
containing an intact antigen I/II), DRB1*04 positive subjects exhibited lower responses,
though not statistically significant. This suggests that when encountering the entire antigen,
in contrast to the selected peptides, these DRB1*04 positive subjects were not able to
respond as well as controls (Figure 6).
4. DISCUSSION
The goal of this study was to gain a molecular understanding of S. mutans-induced caries
with the goal of future vaccine design and biomarker identification to predict caries
susceptibility. Previous literature suggested that HLA-DRB1*04 appears to be a caries
susceptibility allele in Caucasians. Our current results do not disprove this notion, but argue
for a more nuanced and complicated picture regarding the immunogenetics of caries
development.
Consistent with the link between DRB1*04 and caries, this study revealed a large reduction
in TIgA of DRB1*04 positive subjects (27.6%) compared to controls (Figure 3). Though the
TIgA difference was not statistically significant, the large observed difference may prove
clinically important, both to mucosal immunity and caries specifically. Less TIgA putatively
leads to a decreased ability to respond to cariogenic organisms.
Also in agreement with the link between DRB1*04 and caries, DRB1*04 positive subjects
exhibited reduced reactivity to a single epitope in this study, 834–853. Though this observed
difference was not statistically significant, the fact that this difference occurs across multiple
measures suggests that it may be both biologically and clinically important (Figures 4–6).
This research needs to be examined in a larger population to verify the differences observed
in this study. Future research is necessary to determine if vaccination to this epitope might
boost caries immunity since, among other things, 834–853 is crucially involved in a primary
gp340 binding domain.
Results suggest that DRB1*04 positive subjects exhibit a lower SIgA response to I/II of S.
mutans NG8 compared to controls (Figure 6). This yet suggests that I/II is important but that
the selected epitopes do not account for all immunoreactivity. Both GTFs and GBPs also
play an important role in caries development. Researchers have hypothesized that HLA-II
alleles produce differences in immunological responses to GbpB immunogenic epitopes
[28,29]. Nevertheless, results from our lab demonstrate that DRB1*04 positive subjects are
slightly higher responders to an I/II-deficient strain (PC 3370) of S. mutans, as well as to the
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I/II replete NG8 and UA159 strains (data not shown) than controls. This means that these
subjects are immunologically competent to GBPs and other adhesins, compared to controls.
Additionally, by subtracting the I/II-deficient strain’s reactivity from NG8’s activity, an
indirect measure of reactivity to I/II in its entirety is determined, demonstrating that I/II is
where DRB1*04 positive subjects may exhibit a lower immune response (Figure 6). This is
in agreement with a previous study where two DRB1*04 allelic variants demonstrated lower
SIgA reactivity than controls to the entire I/II antigen [12]. Unfortunately, a purified sample
of the entire sequence of I/II was not available. This indirect measurement is especially
helpful since I/II in its entirety is notoriously unstable and degrades rapidly in vitro; thus it is
very difficult to study in isolation as a whole.
It is interesting to note that of all 10 epitopes assayed, one epitope (834–853; which
straddles the carboxy-terminus of the V region and encompasses most of the P1 region)
demonstrated the opposite response across all immunological measures (Figures 4 and 5,
and other data not shown) from the other nine epitopes. This epitope was originally
identified in a preliminary laboratory study, using pooled saliva, as being most important
after normalizing those data (data not shown). These results regarding epitope 834–853
support our initial hypothesis. Taking into account those data suggesting lower reactivity to
the entire I/II antigen, 834–853 may be one part of a discontinuous epitope involved in
attachment to the acquired salivary pellicle on the tooth surface, and DRB1*04 subjects may
have less specificity and functional activity in responding to this epitope.
There is new data that suggests that this may be the case. Although the A and P regions are
important as areas that interact and serve as docking sites for discontinuous epitopes, the
variable region is now known to also be very important [26]. Researchers have suggested
that I/II presents a lectin-like (i.e., carbohydrate-binding) domain in the middle of the V
region important in bacterial adhesion [30]; for example, in binding fibronectin [31] or
“collagen, laminin, keratin, fibrinogen and other oral microorganisms” [32]. It is very
interesting to note that 834–853 encompasses the very residues (interacting with 464–471,
which was not examined in this study) that make up the distal arm of the V region (the
reactive part of the arm, made up of proximal and distal regions) of what has recently been
called a hinge-like area of I/II. This hinge-like area interfaces with all three major regions
(A, V, and P) of I/II and supports the flexure of what is now known to make up most of the
length of the I/II stalk [26]. Not only does the distal arm provide flexing in unison by the A,
V, and P regions, but it is also involved in governing intermolecular interactions among the
backbone of I/II such as solidifying the proximal arm’s hydrophobicity, which is locked
interiorly by hydrogen bonding and salt-bridges [30]. Even more, the V region exhibits
sequence homology with S. mutans GbpC, which binds glucan that is synthesized by GTFs
and aids development of biofilm. Nevertheless, it is clear that the V region does not act
alone but rather functions in tandem via its distal arm (serving as a sort of center for
functionality) with its sister domains.
It is the three-dimensional interaction of the A, V, and P regions that predominantly affects
S. mutans attachment to a dental pellicle protein, gp340, alternatively called salivary
agglutinin (SAG) or DMBT1 (deleted in malignant brain tumors 1). Human gp340 belongs
to a family of innate immune proteins that are characterized by scavenger receptor cysteine-
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rich (SRCR) proteins. There are SRCR domains along the entire length of gp340, which
serve as the binding sites for the specific arrangement of particular sections of the A, V, and
P regions within I/II. When in the planktonic form, SRCRs provide gp340 the ability to
serve as a pattern recognition receptor [32]. Thus, gp340 “promotes bacterial aggregation
and clearance” [33] when it encounters S. mutans planktonically. However, when the
glycoprotein is embedded in the tooth pellicle or on the epithelium or on microbes
themselves (i.e., immobilized in dental biofilm), it instead serves as a receptor for
streptococcal attachment [34].
S. mutans I/II was recently demonstrated to be a singular protein, very different from what
has heretofore been understood about other proteins in nature. Researchers demonstrated
that it is a hybrid structure of α-helices and polyproline type II (PPII) helices intimately
associated with each other [26]. PPII helices are more flexible than other regular structures
such as α-helices or β-sheets, but are nonetheless solid due to the “rigidity of the proline
ring,” echoing what was previously said about the functionality of the distal arm of the V
region, which is also linked and a part of the amino terminus of the P region, whose
existence provides a hinge-region allowing the I/II stalk to flex as a unit and yet maintain a
V region hydrophobic core that is locked in place.
What insight does this recently discovered structure provide? For one, it demonstrates that
A3 and P1 (and V) interactions, of which 834–853 is crucially involved, serves as a primary
gp340 binding domain. It also demonstrates that a secondary gp340 binding site is located in
the C-terminal domain. This means that after the globular V region (coupled with the amino
terminus of the P region and the carboxy terminus of the A region) initially adheres to the
salivary pellicle, the distal arm can flex to such a degree that the C-terminal domain, which
abuts the anchor motif on S. mutans itself, can actually bind gp340 as well. Thus, if host
SIgA sufficiently responds to this very particular region, I/II will not be able to take
advantage of these binding sites and the process of caries will be abated or slowed.
Alternatively, if there were low SIgA responses to this particular epitope located in the distal
arm region, it would follow that I/II could take full advantage of its array of virulent
mechanisms, which fits the hypothesis with regard to the DRB1*04 positive group and the
epitope found at 834–853. That the control group may exhibit a better ability to naturally
fight caries while still in its early stages is supported by the fact of higher reactivity to the
834–853 epitope.
Ultimately, however, how antibodies relate to their HLA gene-encoding counterparts
remains to be fully explored. As these fundamental mechanisms become better understood
in the long-term [18], our ability to design vaccines will not only increase but also enable us
to individually tailor immunizations. Caries is also affected in large part by exogenous
variables such as oral hygiene, diet, fluoride exposure, as well as psycho-social factors, all
of which may change over time in different ways. If a larger and more comprehensive study
confirms what is observed in this study, it will also be necessary to control, to the extent
possible, other environmental variables such as those mentioned.
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5. CONCLUSION
These results show that DRB1*04 positive subjects have an observed reduction in TIgA
compared to controls, an observational difference never before published. Also, it
demonstrates that a particular epitope may play a significant role in the caries process
depending on the immune status of the host. This epitope (834–853) located in the distal arm
of the V region (also connected to the P1 region) is probably very important, and provides a
biological connection between reduced SIgA reactivity in DRB1*04 positive subjects to its
binding site, and therefore greater adherence to the tooth structure, which can lead to caries.
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Figure 1.
Schematic and diagramatic representations of the surface protein adhesin, antigen I/II.
Antigen I/II is comprised of the following regions (and residues): the signal sequence (1–
38), a pre-A region (39–120), the A-region (121–447), V-region (aa 448–839), P-region
(840–983), and the C-terminal region (984–1463), and regions for anchor proteins
associated with the bacterial cell wall including the LPxTG anchor region (CWA) (1464–
1561). The A-region consists of four alanine-rich tandem repeats, specifically A1 (121–
201), A2 (202–283), A3 (284–365), and A4 (366–447). The P-region also consists of three
to four repeated regions (represented here as four) with about 35 percent proline content,
including P1 (840–878), P2 (879–917), P3 (918–956), and P4 (957–983) [26,27].
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Figure 2.
The log transformed number of S. mutans colony forming units/mL of whole saliva for
DRB1*04 positive (n = 16) and negative subjects (n = 16). These data are reported as
natural log means and standard errors of the mean.
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Figure 3.
Human salivary total IgA among HLA-DRB1*04 positive (n = 16) and negative subjects (n
= 16).
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Figure 4.
Human salivary IgA specific activity of HLA-DRB1*04 positive (n = 16) and negative
subjects (n = 16) to 10 selected putative epitopes of S. mutans I/II. Specific activity was
calculated using the natural log of the ratio of each subject’s SIgA OD reading for each
epitope in triplicate to the total IgA OD for each subject. These data are reported in natural
log values as means and standard errors of the mean.
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Figure 5.
Human salivary IgA reactivity ratios of HLA-DRB1*04 positive (n = 16) and negative
subjects (n = 16) to 10 selected putative epitopes of S. mutans I/II/S. mutans UA159 whole
cells (UA159). These data are reported in natural log values as means and standard errors of
the mean.
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Figure 6.
Human salivary IgA immunoreactivity to the entire I/II antigen on NG8 (indirect measure)
in HLA-DRB1*04 positive (n = 16) and negative (n = 16) subjects. Reactivity to NG8 and a
I/II-deficient strain (PC3370) was determined and the data were calculated by subtracting
OD 490 nm PC3370 values from NG8 values to focus on epitopes of I/II. These data are
reported in optical density absorbance (490 nm) as means and standard errors of the mean.
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